New safety signals around GLP‑1 drugs and what they mean Recent research presented to clinicians and researchers has linked glucagon‑like peptide‑1 (GLP‑1) receptor agonists — the class that includes widely used medicines such as semaglutide and other brand names — with a small but measurable…
Continue reading...
Continue reading...